06-318 | Anti-TGFβR Type II Antibody, CT

06-318
200 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RWBRbPurifiedPolyclonal Antibody
      Description
      Catalogue Number06-318
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-TGFβR Type II Antibody, CT
      OverviewThe TGFβ Type II receptor is a low abundant protein, approximately 200 receptors/cell
      References
      Product Information
      FormatPurified
      Presentation0.1M Tris-glycine, pH 7.4
      Applications
      ApplicationThis Anti-TGFβR Type II Antibody, CT is validated for use in WB for the detection of TGFβR Type II.
      Key Applications
      • Western Blotting
      Biological Information
      Immunogenpeptide corresponding to the 16 C-Terminal residues (CSEEKIPEDGSLNTTK) of the mature human TGFβ receptor
      HostRabbit
      Specificityp75 TGFβ Type II receptors; does not cross-react with other identified receptors
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized.
      Gene Symbol
      • TGFBR2
      • AAT3
      • TAAD2
      • TbetaR-II
      • TGFR-2
      • RIIC
      • MFS2
      • HNPCC6
      • FAA3
      • TGFbeta-RII
      Purification MethodProtein G Chromatography
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P37173 # On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta.
      COFACTOR: Magnesium or manganese (By similarity).
      SIZE: 567 amino acids; 64568 Da
      SUBUNIT: Binds to DAXX.
      SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
      PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.
      DISEASE: SwissProt: P37173 # Defects in TGFBR2 are the cause of hereditary non- polyposis colorectal cancer type 6 (HNPCC6) [MIM:190182]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term suspected HNPCC or incomplete HNPCC can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. HNPCC6 is a type of colorectal cancer complying with the clinical criteria of HNPCC, except that the onset of cancer was beyond 50 years of age in all cases. & Defects in TGFBR2 are a cause of esophageal cancer [MIM:133239]. & Defects in TGFBR2 are the cause of Marfan syndrome type II (MFS2) [MIM:154705]. Marfan syndrome (MFS) is an extracellular matrix disorder with cardinal manifestations in the eye, skeleton and cardiovascular systems, and is associated with defects in the gene encoding fibrillin 1 (FBN1). A second type of the disorder is caused by mutations in a second locus MFS2. Identification of a 3p24.1 chromosomal breakpoint disrupting the gene TGFBR2 in a Japanese individual with Marfan syndrome led to consider TGFBR2 as the gene underlying association with MFS at the MSF2 locus. & Defects in TGFBR2 are a cause of Loeys-Dietz aortic aneurysm syndrome (LDAS) [MIM:609192]. LDAS is an aortic aneurysm syndrome characterized by widely spaced eyes (hypertelorism), bifid uvula and/or cleft palate, and generalized arterial tortuosity with ascending aortic aneurysm and aortic dissection. This syndrome shows autosomal dominant inheritance and variable clinical expression. Other findings in multiple systems include craniosynostosis, structural brain abnormalities, mental retardation, congenital heart disease and aneurysms with dissection throughout the arterial tree. & Defects in TGFBR2 are the cause of familial thoracic aortic aneurysm 3 (AAT3) [MIM:608967]; also known as familial thoracic aortic aneurysm and dissection (TAAD). Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' or 'Erdheim cystic medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance. AAT3 is an autosomal dominant disorder with reduced penetrance and variable expression.
      SIMILARITY: SwissProt: P37173 ## Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily. & Contains 1 protein kinase domain.
      Molecular Weight75kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated by immunoblot on freshly prepared MG63 osteosarcoma cell lysate or TF-1 human erythroleukemia cell lysate
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage Conditions1 year at -20°C
      Packaging Information
      Material Size200 µg
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SDS

      Title

      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-TGFbeta;R Type II, CT - 13284 13284
      Anti-TGFbeta;R Type II, CT - 32638 32638

      References

      Reference overviewPub Med ID
      Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers.
      Li, Y; Cao, H; Jiao, Z; Pakala, SB; Sirigiri, DN; Li, W; Kumar, R; Mishra, L
      Cancer research  70  8159-68  2010

      Show Abstract
      20889724 20889724
      Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth.
      Daly, AC; Randall, RA; Hill, CS
      Molecular and cellular biology  28  6889-902  2008

      Show Abstract Full Text Article
      18794361 18794361
      Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase.
      Lin, H Y, et al.
      Cell, 68: 775-85 (1992)  1992

      Show Abstract
      1310899 1310899

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      06-227 Anti-TGFβR Type II Antibody, NT Show Pricing & Availability

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies